| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies BD Lehmann, JA Bauer, X Chen, ME Sanders, AB Chakravarthy, Y Shyr, ... The Journal of clinical investigation 121 (7), 2750-2767, 2011 | 6219 | 2011 |
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance JA McCubrey, LS Steelman, WH Chappell, SL Abrams, EWT Wong, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773 (8), 1263-1284, 2007 | 3060 | 2007 |
| Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection BD Lehmann, B Jovanović, XI Chen, MV Estrada, KN Johnson, Y Shyr, ... PloS one 11 (6), e0157368, 2016 | 1467 | 2016 |
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ... Clinical cancer research 19 (19), 5533-5540, 2013 | 877 | 2013 |
| Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes BD Lehmann, JA Pietenpol The Journal of pathology 232 (2), 142-150, 2014 | 572 | 2014 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 568 | 2014 |
| Senescence-associated exosome release from human prostate cancer cells BD Lehmann, MS Paine, AM Brooks, JA McCubrey, RH Renegar, R Wang, ... Cancer research 68 (19), 7864-7871, 2008 | 524 | 2008 |
| Subtyping of triple‐negative breast cancer: implications for therapy VG Abramson, BD Lehmann, TJ Ballinger, JA Pietenpol Cancer 121 (1), 8-16, 2015 | 426 | 2015 |
| PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors BD Lehmann, JA Bauer, JM Schafer, CS Pendleton, L Tang, KC Johnson, ... Breast Cancer Research 16, 1-14, 2014 | 379 | 2014 |
| New strategies for triple-negative breast cancer—deciphering the heterogeneity IA Mayer, VG Abramson, BD Lehmann, JA Pietenpol Clinical cancer research 20 (4), 782-790, 2014 | 373 | 2014 |
| TNBCtype: a subtyping tool for triple-negative breast cancer X Chen, J Li, WH Gray, BD Lehmann, JA Bauer, Y Shyr, JA Pietenpol Cancer informatics 11, CIN. S9983, 2012 | 290 | 2012 |
| Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors LS Steelman, PM Navolanic, ML Sokolosky, JR Taylor, BD Lehmann, ... Oncogene 27 (29), 4086-4095, 2008 | 202 | 2008 |
| BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition KE Hutchinson, D Lipson, PJ Stephens, G Otto, BD Lehmann, PL Lyle, ... Clinical Cancer Research 19 (24), 6696-6702, 2013 | 199 | 2013 |
| Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer KD Yu, R Zhu, M Zhan, AA Rodriguez, W Yang, S Wong, A Makris, ... Clinical cancer research 19 (10), 2723-2733, 2013 | 199 | 2013 |
| Triple-negative breast cancer: molecular subtypes and new targets for therapy BD Lehmann, JA Pietenpol, AR Tan American Society of Clinical Oncology Educational Book 35 (1), e31-e39, 2015 | 194 | 2015 |
| Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes BD Lehmann, A Colaprico, TC Silva, J Chen, H An, Y Ban, H Huang, ... Nature communications 12 (1), 6276, 2021 | 175 | 2021 |
| Clinical implications of molecular heterogeneity in triple negative breast cancer BD Lehmann, JA Pietenpol The Breast 24, S36-S40, 2015 | 146 | 2015 |
| A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and … B Jovanović, IA Mayer, EL Mayer, VG Abramson, A Bardia, ME Sanders, ... Clinical Cancer Research 23 (15), 4035-4045, 2017 | 143 | 2017 |
| p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3 WH Chappell, BD Lehmann, DM Terrian, SL Abrams, LS Steelman, ... Cell cycle 11 (24), 4579-4588, 2012 | 142 | 2012 |
| Targeting prostate cancer based on signal transduction and cell cycle pathways JT Lee, BD Lehmann, DM Terrian, WH Chappell, F Stivala, M Libra, ... Cell cycle 7 (12), 1745-1762, 2008 | 139 | 2008 |